Magnesium treatment in alcoholics: A randomized clinical trial

<p>Abstract</p> <p>Background</p> <p>Magnesium (Mg) deficiency is common among alcoholics. Earlier research suggests that Mg treatment may help to normalize elevated enzyme activities and some other clinically relevant parameters among alcoholics but the evidence is wea...

Full description

Bibliographic Details
Main Authors: Poikolainen Kari, Alho Hannu
Format: Article
Language:English
Published: BMC 2008-01-01
Series:Substance Abuse Treatment, Prevention, and Policy
Online Access:http://www.substanceabusepolicy.com/content/3/1/1
_version_ 1817994325584248832
author Poikolainen Kari
Alho Hannu
author_facet Poikolainen Kari
Alho Hannu
author_sort Poikolainen Kari
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Magnesium (Mg) deficiency is common among alcoholics. Earlier research suggests that Mg treatment may help to normalize elevated enzyme activities and some other clinically relevant parameters among alcoholics but the evidence is weak.</p> <p>Methods</p> <p>The effect of Mg was studied in a randomized, parallel group, double-blind trial. The patients were first treated for alcohol withdrawal symptoms and then received for 8 weeks either 500 mg of Mg divided into two tablets or matching placebo. Measurements were made at the beginning and in the end of the Mg treatment period. The primary outcome was serum gamma-glutamyltransferase (S-GGT) activity; secondary outcomes included aspartate-aminotransferase (S-AST) and alanine-aminotransferase (S-ALT) activity.</p> <p>Results</p> <p>The number of randomized patients (completers) was 64 (27) in the treatment and 54 (31) in the control group. In intention-to-treat-analyses and in most analyses of study completers, there were no significant differences between the Mg-treated and placebo groups in the outcome variables. When baseline serum Mg level, coffee intake, and the number of unused Mg tablets were controlled for in a multivariate regression model, after-treatment serum Mg levels were found to be higher among the Mg-treated group than in the placebo group (t-test 3.334, df = 53, p = 0.002). After controlling for age, body weight, baseline alcohol intake, subsequent change in alcohol intake and baseline S-AST, the after-treatment S-AST levels were found to be lower among the Mg-treated group than in the placebo group (t-test 2.061, df = 49, p = 0.045).</p> <p>Conclusion</p> <p>Mg treatment may speed up the S-AST decrease in compliant patients. This might decrease the risk of death from alcoholic liver disease.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov ID NCT00325299</p>
first_indexed 2024-04-14T01:51:24Z
format Article
id doaj.art-329787e95de04820989556612dd1d310
institution Directory Open Access Journal
issn 1747-597X
language English
last_indexed 2024-04-14T01:51:24Z
publishDate 2008-01-01
publisher BMC
record_format Article
series Substance Abuse Treatment, Prevention, and Policy
spelling doaj.art-329787e95de04820989556612dd1d3102022-12-22T02:19:20ZengBMCSubstance Abuse Treatment, Prevention, and Policy1747-597X2008-01-0131110.1186/1747-597X-3-1Magnesium treatment in alcoholics: A randomized clinical trialPoikolainen KariAlho Hannu<p>Abstract</p> <p>Background</p> <p>Magnesium (Mg) deficiency is common among alcoholics. Earlier research suggests that Mg treatment may help to normalize elevated enzyme activities and some other clinically relevant parameters among alcoholics but the evidence is weak.</p> <p>Methods</p> <p>The effect of Mg was studied in a randomized, parallel group, double-blind trial. The patients were first treated for alcohol withdrawal symptoms and then received for 8 weeks either 500 mg of Mg divided into two tablets or matching placebo. Measurements were made at the beginning and in the end of the Mg treatment period. The primary outcome was serum gamma-glutamyltransferase (S-GGT) activity; secondary outcomes included aspartate-aminotransferase (S-AST) and alanine-aminotransferase (S-ALT) activity.</p> <p>Results</p> <p>The number of randomized patients (completers) was 64 (27) in the treatment and 54 (31) in the control group. In intention-to-treat-analyses and in most analyses of study completers, there were no significant differences between the Mg-treated and placebo groups in the outcome variables. When baseline serum Mg level, coffee intake, and the number of unused Mg tablets were controlled for in a multivariate regression model, after-treatment serum Mg levels were found to be higher among the Mg-treated group than in the placebo group (t-test 3.334, df = 53, p = 0.002). After controlling for age, body weight, baseline alcohol intake, subsequent change in alcohol intake and baseline S-AST, the after-treatment S-AST levels were found to be lower among the Mg-treated group than in the placebo group (t-test 2.061, df = 49, p = 0.045).</p> <p>Conclusion</p> <p>Mg treatment may speed up the S-AST decrease in compliant patients. This might decrease the risk of death from alcoholic liver disease.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov ID NCT00325299</p>http://www.substanceabusepolicy.com/content/3/1/1
spellingShingle Poikolainen Kari
Alho Hannu
Magnesium treatment in alcoholics: A randomized clinical trial
Substance Abuse Treatment, Prevention, and Policy
title Magnesium treatment in alcoholics: A randomized clinical trial
title_full Magnesium treatment in alcoholics: A randomized clinical trial
title_fullStr Magnesium treatment in alcoholics: A randomized clinical trial
title_full_unstemmed Magnesium treatment in alcoholics: A randomized clinical trial
title_short Magnesium treatment in alcoholics: A randomized clinical trial
title_sort magnesium treatment in alcoholics a randomized clinical trial
url http://www.substanceabusepolicy.com/content/3/1/1
work_keys_str_mv AT poikolainenkari magnesiumtreatmentinalcoholicsarandomizedclinicaltrial
AT alhohannu magnesiumtreatmentinalcoholicsarandomizedclinicaltrial